CANOPE: Prognostic and Predictive Markers of Treatment Response in Patients With Pancreatic Adenocarcinoma
Study Details
Study Description
Brief Summary
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, ... ) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Overall Survival (OS) rate [Up to 7 years from the date of initial cancer diagnosis (or until death if it occurs before 17 years)]
Defined as the time interval between the start date of treatment (surgery, first cycle of L1 chemotherapy, or first radiotherapy session) and the date of death regardless of the cause. Living or lost to follow-up patients will be censored at the date of the last news
Secondary Outcome Measures
- Progression-free survival (PFS) rate [Up to 7 years]
defined as the time interval between the start date of treatment (surgery, first cycle of L1 chemotherapy, or first radiotherapy session) and the date of first progression or date of death regardless of the cause. Living patients without progression or lost to follow-up will be censored at the date of the last news
- Number of patient with Objective response rate [Up to 7 years]
Evaluation according to RECIST v1.1, Choi or iRECIST criteria
- Number of patient with Stability rate [Up to 7 years]
Evaluation according to RECIST v1.1, Choi or iRECIST criteria
- Number of patient with Tumor progression [Up to 7 years]
Evaluation according to RECIST v1.1, Choi or iRECIST criteria
- Number of patient with grade 3/4 treatment-related toxicities [Up to 7 years]
Evaluation according to CTCAE v5.0 classification
- Number of patients who received maintenance treatment in the first line [Up to 7 years]
- Number of patients who received second and third line treatment [Up to 7 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with histologically confirmed pancreatic adenocarcinoma.
-
Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
-
Diagnosis between January 1, 2003, and December 31, 2030.
-
First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
-
Age ≥ 18 years.
-
Written informed consent
Exclusion Criteria:
-
Patient under guardianship, curatorship, or judicial protection.
-
Pregnant or breastfeeding women.
-
Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
-
Refusal to participate in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Jean Minjoz | Besançon | France | ||
| 2 | Hôpital Beaujon | Clichy | France | ||
| 3 | CHU - Henri Mondor | Créteil | France | ||
| 4 | CHU Lille | Lille | France | ||
| 5 | Centre Léon Bérard | Lyon | France | ||
| 6 | HRU Nancy Site Brabois | Nancy | France | ||
| 7 | Hôpital Georges Pompidou | Paris | France | ||
| 8 | Hôpital Saint Antoine | Paris | France | ||
| 9 | Institut Mutualiste Montsouris | Paris | France | ||
| 10 | CHU Poitiers | Poitiers | France | ||
| 11 | CHU Reims | Reims | France | ||
| 12 | CHU Pontchaillou | Rennes | France | ||
| 13 | Institut Curie | Saint-Cloud | France | ||
| 14 | IHU - Institut de chirurgie guidée par l'imagerie | Strasbourg | France | ||
| 15 | Hôpital Paul Brousse | Villejuif | France |
Sponsors and Collaborators
- GERCOR - Multidisciplinary Oncology Cooperative Group
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CANOPE GB-121